StreetInsider.com News Articles

Form 4 UNITED THERAPEUTICS Corp For: Aug 06 Filed by: ROTHBLATT MARTINE A

Fri, 07 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260807/26891564.html

Form 4 UNITED THERAPEUTICS Corp For: Aug 06 Filed by: ROTHBLATT MARTINE A

Fri, 07 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260807/26891564.html

Form 4 UNITED THERAPEUTICS Corp For: Aug 06 Filed by: MAHON PAUL A

Thu, 06 Aug 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260806/26884874.html

Form 4 UNITED THERAPEUTICS Corp For: Aug 06 Filed by: MAHON PAUL A

Thu, 06 Aug 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260806/26884874.html

Form 4 UNITED THERAPEUTICS Corp For: Aug 05 Filed by: ROTHBLATT MARTINE A

Thu, 06 Aug 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260806/26884848.html

Form 4 UNITED THERAPEUTICS Corp For: Aug 05 Filed by: ROTHBLATT MARTINE A

Thu, 06 Aug 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260806/26884848.html

Form 144 UNITED THERAPEUTICS Corp Filed by: MAHON PAUL A

Thu, 06 Aug 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260806/26883354.html

Form 144 UNITED THERAPEUTICS Corp Filed by: MAHON PAUL A

Thu, 06 Aug 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260806/26883354.html

United Therapeutics Corp. (UTHR) PT Lowered to $515 at Morgan Stanley

Thu, 06 Aug 2026 08:53:14 -0400

Morgan Stanley analyst Terence Flynn lowered the price target on United Therapeutics Corp. (NASDAQ: UTHR) to $515.00 (from $516.00) while maintaining a Equalweight rating.

United Therapeutics Corp. (UTHR) PT Lowered to $677 at RBC Capital

Thu, 06 Aug 2026 06:58:58 -0400

RBC Capital analyst Lisa Walter lowered the price target on United Therapeutics Corp. (NASDAQ: UTHR) to $677.00 (from $704.00) while maintaining a Outperform rating.

United Therapeutics Corp. (UTHR) PT Lowered to $700 at Wells Fargo

Thu, 06 Aug 2026 06:38:35 -0400

Wells Fargo analyst Ben Burnett lowered the price target on United Therapeutics Corp. (NASDAQ: UTHR) to $700.00 (from $738.00) while maintaining a Overweight rating.

Form 4 UNITED THERAPEUTICS Corp For: Aug 04 Filed by: ROTHBLATT MARTINE A

Wed, 05 Aug 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260805/26875194.html

Form 4 UNITED THERAPEUTICS Corp For: Aug 04 Filed by: ROTHBLATT MARTINE A

Wed, 05 Aug 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260805/26875194.html

United Therapeutics Corp. (UTHR) PT Lowered to $559 at BofA Securities

Wed, 05 Aug 2026 16:22:40 -0400

BofA Securities analyst Greg Harrison lowered the price target on United Therapeutics Corp. (NASDAQ: UTHR) to $559.00 (from $613.00) while maintaining a Neutral rating.

The analyst comments "2Q results included a modest revenue miss of approximately 3%, and management is no longer affirming its prior Tyvaso sales guidance. Beneath the headline, the roughly 4% Y/Y decline in Tyvaso revenue appears to reflect increasing competitive pressure in the product's core indications. To address the slowdown, the company announced plans to double its sales force effective July 2026 to help reaccelerate Tyvaso growth. In response to these developments, we lower our FY26 company

United Therapeutics Corp. (UTHR) PT Lowered to $559 at BofA Securities

Wed, 05 Aug 2026 16:22:40 -0400

BofA Securities analyst Greg Harrison lowered the price target on United Therapeutics Corp. (NASDAQ: UTHR) to $559.00 (from $613.00) while maintaining a Neutral rating.

United Therapeutics (UTHR) Tops Q2 EPS by 18c

Wed, 05 Aug 2026 06:34:01 -0400

United Therapeutics (NASDAQ: UTHR) reported Q2 EPS of $7.27, $0.18 better than the analyst estimate of $7.09. Revenue for the quarter came in at $783.3 million versus the consensus estimate of $807.05 million.

For earnings history and earnings-related data on United Therapeutics (UTHR) click here.

Form 8-K UNITED THERAPEUTICS Corp For: Aug 05

Wed, 05 Aug 2026 06:33:00 -0400

si-local-file:///var/storage/secattach/20260805/26869729.html

Form 8-K UNITED THERAPEUTICS Corp For: Aug 05

Wed, 05 Aug 2026 06:33:00 -0400

si-local-file:///var/storage/secattach/20260805/26869729.html

Form 10-Q UNITED THERAPEUTICS Corp For: Jun 30

Wed, 05 Aug 2026 06:31:00 -0400

si-local-file:///var/storage/secattach/20260805/26869713.html

Form 10-Q UNITED THERAPEUTICS Corp For: Jun 30

Wed, 05 Aug 2026 06:31:00 -0400

si-local-file:///var/storage/secattach/20260805/26869713.html

United Therapeutics Corporation Reports Second Quarter 2026 Financial Results

Wed, 05 Aug 2026 06:30:00 -0400

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended June 30, 2026. Total revenues in the second quarter of 2026 decreased by two percent year-over-year to $783.3 million, compared to $798.6 million in the second quarter of 2025.

“We just submitted what we believe are two of the most important NDAs in rare pulmonary disease history: ralinepag tablets in PAH and Nebulized Tyvaso in IPF,” said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. “We believe that